These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 1916996)

  • 21. Angiotensin-converting enzyme and angiotensin II receptor subtype 1 inhibitors restitute hypertensive internal anal sphincter in the spontaneously hypertensive rats.
    De Godoy MA; Rattan S
    J Pharmacol Exp Ther; 2006 Aug; 318(2):725-34. PubMed ID: 16648368
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Changes in endothelium-derived hyperpolarizing factor in hypertension and ageing: response to chronic treatment with renin-angiotensin system inhibitors.
    Goto K; Fujii K; Kansui Y; Iida M
    Clin Exp Pharmacol Physiol; 2004 Sep; 31(9):650-5. PubMed ID: 15479174
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antagonism between the vascular renin-angiotensin and natriuretic peptide systems in vascular remodelling.
    Itoh H; Nakao K
    Blood Press Suppl; 1994; 5():49-53. PubMed ID: 7534179
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cilazapril suppresses myointimal proliferation after vascular injury: effects on growth factor induction in vascular smooth muscle cells.
    Powell JS; Rouge M; Müller RK; Baumgartner HR
    Basic Res Cardiol; 1991; 86 Suppl 1():65-74. PubMed ID: 1827985
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Role of the renin-angiotensin system in neointima formation after injury in rabbits.
    Janiak P; Libert O; Vilaine JP
    Hypertension; 1994 Dec; 24(6):671-8. PubMed ID: 7995623
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The cellular biology of angiotensin: paracrine, autocrine and intracrine actions in cardiovascular tissues.
    Re RN
    J Mol Cell Cardiol; 1989 Dec; 21 Suppl 5():63-9. PubMed ID: 2697759
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Differential regulation of Na+/H+ antiporter gene expression in vascular smooth muscle cells by hypertrophic and hyperplastic stimuli.
    Rao GN; Sardet C; Pouysségur J; Berk BC
    J Biol Chem; 1990 Nov; 265(32):19393-6. PubMed ID: 2174035
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Angiotensin-converting enzyme 2 is a critical determinant of angiotensin II-induced loss of vascular smooth muscle cells and adverse vascular remodeling.
    Patel VB; Zhong JC; Fan D; Basu R; Morton JS; Parajuli N; McMurtry MS; Davidge ST; Kassiri Z; Oudit GY
    Hypertension; 2014 Jul; 64(1):157-64. PubMed ID: 24799609
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Heterogeneity of endothelium-dependent vasodilator effects of angiotensin-converting enzyme inhibitors: role of bradykinin generation during ACE inhibition.
    Mombouli JV; Vanhoutte PM
    J Cardiovasc Pharmacol; 1992; 20 Suppl 9():S74-82. PubMed ID: 1282634
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The molecular basis of cardiovascular hypertrophy: the role of the renin-angiotensin system.
    Paul M; Ganten D
    J Cardiovasc Pharmacol; 1992; 19 Suppl 5():S51-8. PubMed ID: 1381795
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Vascular smooth muscle cell hypertrophy vs. hyperplasia. Autocrine transforming growth factor-beta 1 expression determines growth response to angiotensin II.
    Gibbons GH; Pratt RE; Dzau VJ
    J Clin Invest; 1992 Aug; 90(2):456-61. PubMed ID: 1644917
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Suppression of the vascular response to injury: the role of angiotensin-converting enzyme inhibitors.
    Powell JS; Muller RK; Baumgartner HR
    J Am Coll Cardiol; 1991 May; 17(6 Suppl B):137B-142B. PubMed ID: 1826694
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tissue renin-angiotensin system: a site of drug action?
    Zimmerman BG; Dunham EW
    Annu Rev Pharmacol Toxicol; 1997; 37():53-69. PubMed ID: 9131246
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mitogen-activated protein kinase activity regulation role of angiotensin and endothelin systems in vascular smooth muscle cells.
    Kubo T; Ibusuki T; Chiba S; Kambe T; Fukumori R
    Eur J Pharmacol; 2001 Jan; 411(1-2):27-34. PubMed ID: 11137855
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Vascular injury induces angiotensinogen gene expression in the media and neointima.
    Rakugi H; Jacob HJ; Krieger JE; Ingelfinger JR; Pratt RE
    Circulation; 1993 Jan; 87(1):283-90. PubMed ID: 8419017
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inhibitors of angiotensin-converting enzyme prevent myointimal proliferation after vascular injury.
    Powell JS; Clozel JP; Müller RK; Kuhn H; Hefti F; Hosang M; Baumgartner HR
    Science; 1989 Jul; 245(4914):186-8. PubMed ID: 2526370
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Renin-angiotensin system and atherothrombotic disease: from genes to treatment.
    Jacoby DS; Rader DJ
    Arch Intern Med; 2003 May; 163(10):1155-64. PubMed ID: 12767951
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Differential regulation of p27kip1 levels and CDK activities by hypertrophic and hyperplastic agents in vascular smooth muscle cells.
    Rao GN
    Biochim Biophys Acta; 1999 Jan; 1448(3):525-32. PubMed ID: 9990305
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Vascular protection: current possibilities and future perspectives.
    Lüscher TF
    Int J Clin Pract Suppl; 2001 Jan; (117):3-6. PubMed ID: 11715356
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Angiotensin and cell growth: a link to cardiovascular hypertrophy?
    Schelling P; Fischer H; Ganten D
    J Hypertens; 1991 Jan; 9(1):3-15. PubMed ID: 1848256
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.